论文部分内容阅读
目的评价伽玛刀作为首选方法治疗分泌型垂体腺瘤的疗效。方法回顾性分析1995年7月至2003年12月应用伽玛刀作为首选治疗120例分泌型垂体瘤患者的临床资料。治疗等剂量曲线45%~70%、周边剂量15~32Gy(平均28.5Gy),中心剂量为35~70Gy(平均45.5Gy),靶点165个(平均1~3个)。结果120例患者中111例获得随访,随访时间12~72个月,平均36个月。随访病例内分泌激素水平控制率为48.6%;肿瘤生长控制率96.2%;垂体功能低下发生率为2.7%;肿瘤卒中发生率0.9%。结论伽玛刀作为首选治疗分泌型垂体腺瘤安全、有效,肿瘤生长控制良好。
Objective To evaluate the efficacy of gamma knife as the first choice for the treatment of secretory pituitary adenomas. Methods The clinical data of 120 patients with secretory pituitary adenoma treated with gamma knife as the first choice from July 1995 to December 2003 were retrospectively analyzed. The isodose dose curve was 45% -70%, peripheral dose was 15-32Gy (average 28.5Gy), central dose was 35-70Gy (average 45.5Gy) and target was 165 (average 1-3). Results Of the 120 patients, 111 cases were followed up for 12 to 72 months with an average of 36 months. Follow-up of patients with endocrine hormone control rate was 48.6%; tumor growth control rate was 96.2%; hypopituitarism was 2.7%; tumor incidence of 0.9%. Conclusion Gamma knife is the first choice for the treatment of secretory pituitary adenoma, which is safe and effective and has good tumor growth control.